Inozyme Pharma, Inc. (INZY) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Inozyme Pharma, Inc. (INZY) Bundle
Discover the true potential of Inozyme Pharma, Inc. (INZY) with our advanced DCF Calculator! Adjust key assumptions, explore various scenarios, and evaluate how different changes affect Inozyme Pharma's valuation – all within a single Excel template.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -20.7 | -56.8 | -56.0 | -65.9 | -74.8 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .1 | .2 | 1.1 | 1.2 | .8 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -20.8 | -57.0 | -57.0 | -67.1 | -75.6 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 47.1 | 159.9 | 111.8 | 127.9 | 188.6 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .1 | .2 | .1 | .1 | .4 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | -12.4 | -.1 | -.1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .9 | 3.1 | 2.4 | 2.5 | 1.2 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.1 | -.6 | -.4 | -.4 | -.3 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -19.6 | -56.4 | -56.8 | -65.4 | -75.6 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -18.9 | -42.3 | -69.0 | -64.5 | -76.9 | -.8 | .0 | .0 | .0 | .0 |
| WACC, % | 10.55 | 10.63 | 10.64 | 10.6 | 10.64 | 10.61 | 10.61 | 10.61 | 10.61 | 10.61 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | 12 | |||||||||
| Equity Value | -13 | |||||||||
| Diluted Shares Outstanding, MM | 52 | |||||||||
| Equity Value Per Share | -0.25 |
What You Will Get
- Real INZY Financial Data: Pre-filled with Inozyme Pharma’s historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Inozyme Pharma’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Accurate Inozyme Financials: Gain access to reliable pre-loaded historical data and future forecasts.
- Tailored Forecast Assumptions: Modify highlighted cells for key metrics like WACC, growth rates, and profit margins.
- Real-Time Calculations: Automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
- Interactive Dashboard: Clear charts and summaries to effectively visualize your valuation outcomes.
- Designed for All Users: A user-friendly layout suitable for investors, CFOs, and consultants alike.
How It Works
- Step 1: Download the Excel file for Inozyme Pharma, Inc. (INZY).
- Step 2: Review Inozyme’s pre-filled financial data and projections.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model refresh in real-time as you modify your assumptions.
- Step 5: Evaluate the outputs and leverage the findings for your investment strategies.
Why Choose This Calculator for Inozyme Pharma, Inc. (INZY)?
- Comprehensive Tool: Integrates DCF, WACC, and financial ratio analyses tailored for Inozyme Pharma.
- Customizable Inputs: Modify the yellow-highlighted cells to explore different financial scenarios.
- Detailed Insights: Automatically computes Inozyme’s intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide a solid foundation for analysis.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focused on Inozyme Pharma.
Who Should Use This Product?
- Biotechnology Students: Understand drug development processes and apply them using real-world data.
- Researchers: Integrate advanced models into academic studies or clinical research.
- Investors: Evaluate your investment strategies and analyze the market performance of Inozyme Pharma, Inc. (INZY).
- Analysts: Enhance your analysis with a customizable financial model tailored for biotech firms.
- Healthcare Entrepreneurs: Discover how large biotech companies like Inozyme Pharma, Inc. (INZY) are assessed in the market.
What the Template Contains
- Historical Data: Includes Inozyme Pharma, Inc.’s past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Inozyme Pharma, Inc.'s intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Inozyme Pharma, Inc.’s financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.